Free Trial
NASDAQ:STIM

Neuronetics (STIM) Stock Price, News & Analysis

Neuronetics logo
$3.50 +0.08 (+2.34%)
Closing price 04:00 PM Eastern
Extended Trading
$3.40 -0.10 (-2.83%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Neuronetics Stock (NASDAQ:STIM)

Key Stats

Today's Range
$3.38
$3.53
50-Day Range
$3.37
$4.67
52-Week Range
$0.52
$5.92
Volume
482,238 shs
Average Volume
827,789 shs
Market Capitalization
$231.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Moderate Buy

Company Overview

Neuronetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

STIM MarketRank™: 

Neuronetics scored higher than 32% of companies evaluated by MarketBeat, and ranked 737th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Neuronetics has received no research coverage in the past 90 days.

  • Read more about Neuronetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neuronetics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neuronetics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neuronetics has a P/B Ratio of 6.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Neuronetics' valuation and earnings.
  • Percentage of Shares Shorted

    5.18% of the float of Neuronetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neuronetics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neuronetics has recently increased by 13.92%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Neuronetics does not currently pay a dividend.

  • Dividend Growth

    Neuronetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.18% of the float of Neuronetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neuronetics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neuronetics has recently increased by 13.92%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $826,074.00 in company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of Neuronetics is held by insiders.

  • Percentage Held by Institutions

    53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neuronetics' insider trading history.
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

STIM Stock Analysis - Frequently Asked Questions

Neuronetics' stock was trading at $1.61 at the beginning of 2025. Since then, STIM stock has increased by 117.4% and is now trading at $3.50.

Neuronetics, Inc. (NASDAQ:STIM) posted its earnings results on Tuesday, May, 6th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.08. The company earned $31.98 million during the quarter, compared to the consensus estimate of $29.07 million. Neuronetics had a negative net margin of 53.67% and a negative trailing twelve-month return on equity of 174.15%.
Read the conference call transcript
.

Neuronetics (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics' top institutional shareholders include Fermata Advisors LLC (0.02%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, William Andrew Macan, Robert Cascella, Stephen Furlong and Glenn P Muir.
View institutional ownership trends
.

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK).

Company Calendar

Last Earnings
5/06/2025
Today
7/09/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:STIM
CIK
1227636
Employees
180
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$3.00
Potential Upside/Downside
+56.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.71 million
Pretax Margin
-54.27%

Debt

Sales & Book Value

Annual Sales
$74.89 million
Price / Cash Flow
N/A
Book Value
$0.57 per share
Price / Book
6.18

Miscellaneous

Free Float
59,370,000
Market Cap
$233.04 million
Optionable
Optionable
Beta
1.85
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:STIM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners